Treatment Continuation Guidance in Psoriatic Arthritis Clinical Care

REFERENCES

1. 1.↵
   1. Cañete JD,
   2. Nolla JM,
   3. Queiro R,
   4. Rodríguez MJ,
   5. Ruiz M,
   6. Lizán L;
   7. for the MERECES Working Group

   . Expert consensus on a set of outcomes to assess the effectiveness of biologic treatment in psoriatic arthritis: the MERECES study. J Rheumatol 2020;47:1637–43.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Gossec L,
   2. de Wit M,
   3. Kiltz U,
   4. Braun J,
   5. Kalyoncu U,
   6. Scrivo R,
   7. et al.

   A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012–9.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Coates LC,
   2. FitzGerald O,
   3. Merola JF,
   4. Smolen J,
   5. van Mens LJJ,
   6. Bertheussen H,
   7. et al.

   Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 2018;70:345–55.

   OpenUrl
4. 4.↵
   1. Smolen JS,
   2. Schöls M,
   3. Braun J,
   4. Dougados M,
   5. FitzGerald O,
   6. Gladman DD,
   7. et al.

   Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Singh JA,
   2. Guyatt G,
   3. Ogdie A,
   4. Gladman DD,
   5. Deal C,
   6. Deodhar A,
   7. et al.

   Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res 2019;71:2–29.

   OpenUrl
6. 6.↵
   1. Alharbi S,
   2. Ye JY,
   3. Lee KA,
   4. Chandran V,
   5. Cook RJ,
   6. Gladman DD

   . Remission in psoriatic arthritis: definition and predictors. Semin Arthritis Rheum 2020 Feb 3 (E-pub ahead of print).
7. 7.↵
   1. Gorlier C,
   2. Orbai AM,
   3. Puyraimond-Zemmour D,
   4. Coates LC,
   5. Kiltz U,
   6. Leung YY,
   7. et al.

   Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Ann Rheum Dis 2019;78:201–8.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Aletaha D,
   2. Alasti F,
   3. Smolen JS

   . Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis 2017;76:418–21.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Touma Z,
   2. Thavaneswaran A,
   3. Chandran V,
   4. Pellett F,
   5. Cook RJ,
   6. Gladman DD

   . Clinical and demographic characteristics of erosion-free and erosion-present status in psoriatic arthritis in a cohort study. J Rheumatol 2016;43:1057–62.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. van Mens LJJ,
    2. van de Sande MGH,
    3. van Kuijk AWR,
    4. Baeten D,
    5. Coates LC

    . Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 2018;77:251–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Orbai AM,
    2. Perin J,
    3. Gorlier C,
    4. Coates LC,
    5. Kiltz U,
    6. Leung YY,
    7. et al.

    Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with gender in 458 patients from 14 countries. Arthritis Care Res 2019 Oct 14 (E-pub ahead of print).
12. 12.↵
    1. Holland R,
    2. Højgaard P,
    3. Tillett W,
    4. Gossec L,
    5. de Wit M,
    6. Christensen R,
    7. et al.

    Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as core instrument to measure health-related quality of life in psoriatic arthritis: a systematic review of psychometric properties. J Psoriasis Psoriatic Arthritis 2020;5:12–22.

    OpenUrl
13. 13.↵
    1. Orbai AM,
    2. Holland R,
    3. Leung YY,
    4. Tillett W,
    5. Goel N,
    6. Christensen R,
    7. et al.

    PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials. J Rheumatol 2019;46:990–5.

    OpenUrlAbstract/FREE Full Text